^
BIOMARKER:

EML4-ALK variant 3 + TP53 mutation

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
News
Twitter
Trials
EML4-ALK variant 3 + TP53 mutation
LUAD
alectinib
Resistant: C4 – Case Studies
EML4-ALK variant 3 + TP53 mutation
LUAD
brigatinib
Resistant: C4 – Case Studies
EML4-ALK variant 3 + TP53 mutation
LUAD
lorlatinib
Resistant: D – Preclinical
EML4-ALK variant 3 + TP53 mutation
LUAD
crizotinib
Sensitive: D – Preclinical